Pulmatrix, Inc.

Equities

PULM

US74584P3010

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 01:02:11 24/05/2024 am IST			5-day change	1st Jan Change
1.94 ^USD	-2.02%		+1.04%	+4.30%

17/05	Pulmatrix Files Up to $95 Million Mixed Shelf	MT
15/05	Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled Dhe for Acute Migraine	CI

Pulmatrix, Inc. Announces William Duke, Jr. Tendered His Resignation as Chief Financial Officer, Effective as of the Close of Business on November 22, 2019

October 31, 2019 at 01:40 am IST

Pulmatrix, Inc. announced that on October 25, 2019, William Duke, Jr. tendered his resignation as Chief Financial Officer of the company, effective as of the close of business on November 22, 2019. The resignation of Mr. Duke was not in connection with any disagreement with the company on any matter relating to the company’s operations, policies, or practices.

Latest news about Pulmatrix, Inc.

Pulmatrix Files Up to $95 Million Mixed Shelf	18/05	MT
Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled Dhe for Acute Migraine	15/05	CI
Pulmatrix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Earnings Flash (PULM) PULMATRIX Reports Q1 Revenue $5.9M	10/05	MT
Pulmatrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
Pulmatrix, Inc. Approves Termination of Margaret Wasilewski as Chief Medical Officer	13/03	CI
Pulmatrix Explores Strategic Alternatives	08/01	CI
Pulmatrix Closes Study Of Fungal Lung Infection Treatment, Explores Strategic Alternatives	08/01	DJ
Pulmatrix, Inc. Enters into Further Amendment to Its Agreement with Cipla for the Development of PUR1900 in the Treatment of Allergic Bronchopulmonary Aspergillosis	08/01	CI
Pulmatrix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
Earnings Flash (PULM) PULMATRIX Posts Q3 Revenue $1.8M	09/11	MT
Pulmatrix, Inc. Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole	23/23/23	CI
Pulmatrix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/23/10	CI
Earnings Flash (PULM) PULMATRIX Reports Q2 Revenue $1.8M	10/23/10	MT
Sector Update: Health Care Stocks Easing Late Tuesday	12/23/12	MT
Sector Update: Health Care Stocks Lower Tuesday Afternoon	11/23/11	MT
Pulmatrix Seeks FDA Approval to Launch Phase 2 Trial of Investigational Drug for Acute Migraine Treatment; Shares Rise	11/23/11	MT
Pulmatrix, Inc. Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine	11/23/11	CI
Pulmatrix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12	CI
Earnings Flash (PULM) PULMATRIX Reports Q1 Revenue $1.5M	12/23/12	MT
Pulmatrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	30/23/30	CI
Pulmatrix Doses First Patient in Phase 2b Asthma Trial	06/23/06	MT
Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis in Subjects with Asthma	06/23/06	CI
Pulmatrix Reports Top-Line Results From Acute Migraine Treatment	04/23/04	MT
Pulmatrix, Inc. Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine, for Acute Migraine	04/23/04	CI

Chart Pulmatrix, Inc.

Duration

Period

More charts

Company Profile

Pulmatrix, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE technology. The Companyâs proprietary product pipeline includes treatments for central nervous system (CNS) disorders, such as acute migraine and serious lung diseases, such as chronic obstructive pulmonary disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). The Companyâs product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes. The Companyâs therapeutic candidates include PUR3100, PUR1800, and PUR1900. PUR3100 is the iSPERSE formulation of dihydroergotamine (DHE), for the treatment of acute migraine.

Sector

Biotechnology & Medical Research

Calendar

05/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
PULMATRIX, INC.	+4.30%	72.32L
VERTEX PHARMACEUTICALS INCORPORATED	+10.68%	12TCr
REGENERON PHARMACEUTICALS, INC.	+11.65%	11TCr
BIONTECH SE	-6.31%	2.47TCr
ARGENX SE	-2.33%	2.2TCr
GENMAB A/S	-6.03%	1.93TCr
BEIGENE, LTD.	-13.19%	1.76TCr
WUXI APPTEC CO., LTD.	-40.50%	1.73TCr
NEUROCRINE BIOSCIENCES, INC.	+6.30%	1.4TCr
SAREPTA THERAPEUTICS, INC.	+31.75%	1.21TCr

Bio Therapeutic Drugs

Pulmatrix, Inc.

Equities

PULM

US74584P3010

Biotechnology & Medical Research

Pulmatrix, Inc. Announces William Duke, Jr. Tendered His Resignation as Chief Financial Officer, Effective as of the Close of Business on November 22, 2019

Latest news about Pulmatrix, Inc.

Chart Pulmatrix, Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs